# embecta to Participate in Investor Events
Canonical URL: https://biopharmsignal.com/news/EMBC/embecta-to-participate-in-investor-events
Ticker: EMBC
Company: Embecta
Source: Embecta
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.embecta.com
## Summary

PARSIPPANY, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor

## Article Body
PARSIPPANY, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor
## Recent Company News
- 2026-06-25 13:46 EST — [embecta appoints Nimish Muzumdar as SVP and President, North America](https://biopharmsignal.com/news/EMBC/embecta-appoints-nimish-muzumdar-as-svp-and-president-north-america) — Source: Embecta
- 2026-06-25 13:46 EST — [embecta to Participate in Investor Events](https://biopharmsignal.com/news/EMBC/embecta-to-participate-in-investor-events) — Source: Embecta
- 2026-06-25 13:46 EST — [embecta Completes Acquisition of Owen Mumford Holdings Limited](https://biopharmsignal.com/news/EMBC/embecta-completes-acquisition-of-owen-mumford-holdings-limited) — Source: Embecta
- 2026-06-25 13:46 EST — [embecta to Participate at the 2026 BofA Securities Global Health Care Conference](https://biopharmsignal.com/news/EMBC/embecta-to-participate-at-the-2026-bofa-securities-global-health-care-conference) — Source: Embecta
- 2026-06-25 13:46 EST — [Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance](https://biopharmsignal.com/news/EMBC/embecta-corp-reports-fiscal-2025-fourth-quarter-and-full-year-financial-results-provides-initial-fiscal-year-2026-financial-guidance) — Source: Embecta
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)